Comparative Pharmacology
Head-to-head clinical analysis: DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE versus JANUVIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE versus JANUVIA.
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE vs JANUVIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs incretin hormone activity, enhancing insulin secretion and decreasing glucagon release.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing levels of active incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Oral, 5 mg dapagliflozin / 5 mg saxagliptin once daily, with or without food.
100 mg orally once daily
None Documented
None Documented
Dapagliflozin: terminal half-life ~12.9 hours after oral dose, supporting once-daily dosing. Saxagliptin: terminal half-life ~2.5 hours for parent drug; its active metabolite has half-life ~3.1 hours; overall DPP-4 inhibition sustained for 24 hours.
Terminal elimination half-life: 12.4 hours. Clinical context: supports once-daily dosing in patients with normal renal function.
Dapagliflozin: 75% renal (mainly as inactive glucuronide metabolite, 2% as parent drug), 21% fecal. Saxagliptin: 75% renal (metabolites, 24% as parent drug), 22% fecal. Biliary: negligible.
Renal: approximately 87% (79% unchanged sitagliptin, 16% metabolites). Fecal/biliary: 13% (metabolites and unchanged drug).
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor